Double-blind study of prednicarbate versus fluocortin butyl ester in atopic dermatitis

International Journal of Dermatology

Volumn 35, Issue 2, 1996, Pages 131-132

  Aliaga, Adolfo ^b   Rodriguez M ^b   Armijo, M ^b   Bravo, J ^b   Lopez Avila A ^b   Mascaro, J M ^b   Ferrando, J ^b   Del Rio, R ^b   Lozano, R ^b   Balaguer, A ^b   Botinas, Natalia ^a  

^a Excerpta Medica   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FLUOCORTIN BUTYL; PREDNICARBATE;

ADULT; AGED; ATOPIC DERMATITIS; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PIGMENT DISORDER; SKIN IRRITATION; TOPICAL DRUG ADMINISTRATION;

EID: 9044244907     PISSN: 00119059     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-4362.1996.tb03280.x     Document Type: Conference Paper

References (9)

1. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol (Stockh) 1980; (Suppl 92):44-419.
2. Schmitt EW, Höhler T, Worms G. Long-term observation of treatment with the topical corticosteroid prednicarbate. Z Hautkr 1989; 64(Suppl 1):56-60.
3. Herz G. Tropische Anwendung von Prednicarbat-Losung bei Kindern unter besonderer Berücksichtigung der Reaktion der körpereigenen Cortisolproduktion. Z Hautkr 1989; 64(Suppl 1): 35-39.
4. Vogt HJ, Höler TH. Controlled studies of intraindividual and interindividual design for comparing corticosteroids clinically. In: Christophers E, et al., eds. Topical corticosteroid therapy. A novel approach to safer drugs. New York: Raven Press, 1988:169-179.
5. Schalla W, Schorning S. Potency assessment of topical corticoids in the vasoconstrictor assay and on tuberculininduced inflammation. Skin Pharmacol 1991; 4:191-204.
6. Dykes PJ, Hill S, Marks R. Assessment of the atrophogenicity potential of corticosteroids by ultrasound and by epidermal biopsy under occlusive and nonocclusive conditions. In: Christophers E, et al., eds. Topical corticosteroid therapy. A novel approach to safer drugs. New York: Raven Press, 1988:111-118.
7. Korting HC, Vieluf D, Kerscher M. 0.25% Prednicarbate cream and the corresponding vehicle induce less skin atrophy than 0.1% betamethasone-17-valerate cream and 0.05% clobetasol-17-propionate cream. Eur J Clin Pharmacol 1992; 42:159-161.
8. Herz G. Topical corticosteroids and adrenal suppression: special aspects in pediatrics with prednicarbate. In: Christophers E, et al., eds. Topical corticosteroid therapy. A novel approach to safer drugs. New York: Raven Press, 1988:147-150.
9. Schröpl F. Plasma cortisol concentrations following whole body application of Hoe777 (prednicarbate). In: Christophers E, et al., eds. Topical corticosteroid therapy. A novel approach to safer drugs. New York: Raven Press, 1988:151-154.